
iRhythm Technologies (IRTC) Stock Forecast & Price Target
iRhythm Technologies (IRTC) Analyst Ratings
Bulls say
iRhythm Technologies reported a revenue of $164.3 million in the fourth quarter of 2024, marking a significant year-over-year increase of 24%. The company’s gross margin improved to 70.0%, surpassing consensus expectations, which reflects operational efficiency and cost management. Furthermore, strong domestic demand for its Zio XT and Zio AT products, coupled with international expansion plans, positions iRhythm for sustained double-digit revenue growth in the coming years.
Bears say
iRhythm Technologies, Inc. has projected a significant revenue decline for the first quarter of 2025, estimating it will only account for 22.5% of their full-year revenue guidance of $675-685 million, which raises concerns about the company’s ability to maintain its revenue growth trajectory. Additionally, the company faces potential margin pressure due to anticipated low-single digit pricing headwinds and a risk of flat to down gross margins, compounded by uncertainties surrounding reimbursement rates for extended ECG services that could further strain revenues. Furthermore, the bear case scenario incorporates assumptions of declining average selling prices for their Zio XT product line, which may be only partially mitigated by expected double-digit volume growth and international expansion, illustrating an overall negative financial outlook.
This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.
iRhythm Technologies (IRTC) Analyst Forecast & Price Prediction
Start investing in iRhythm Technologies (IRTC)
Order type
Buy in
Order amount
Est. shares
0 shares